Homology modeling and molecular docking studies for the identification of novel potential therapeutics against human PHD3 as a drug target for type 2 diabetes mellitus

  • Goverdhan Lanka Molecular Modeling Laboratory, Department of Chemistry, Nizam College, Osmania University, Basheerbagh, Hyderabad-500001
  • Revanth Bathula Molecular Modeling Laboratory, Department of Chemistry, Nizam College, Osmania University, Basheerbagh, Hyderabad-500001
  • Manan Bhargavi Molecular Modeling Laboratory, Department of Chemistry, Nizam College, Osmania University, Basheerbagh, Hyderabad-500001
  • Sarita Rajender Potlapally Molecular Modeling Laboratory, Department of Chemistry, Nizam College, Osmania University, Basheerbagh, Hyderabad-500001
DOI https://doi.org/10.22270/jddt.v9i4.3039

Abstract

PHD3 (Prolyl Hydroxylating Domain) 3 protein contains the HRE (Hypoxia Response Element) and plays an important role in regulating HIF subunits. The hydroxylating ability of PHD3 of HIF subunits makes PHD3 is a prominent therapeutic target to control type 2 diabetes mellitus. The structure based approach is used to design novel molecular entities against PHD3 protein. In this present work, a 3D homology model of PHD3 was generated by MODELLER9.9 as the experimental structure of PHD3 is not reported in the protein database.  The 3d structural model of PHD3 refined through energy minimization in VMD-NAMD interface. Active site of the target protein is identified by SiteMap module (Schrodinger suite), manual correlation technique using ClustalW software and literature studies. The asinex library of chemical structures subjected to the molecular docking at the PHD3 active site for the identification of potent inhibitors. The molecules resulted from molecular docking prioritized based on their docking score, glide energy. The ligand molecules are further prioritized with a rescoring parameter Prime-MM/GBSA by calculating binding free energies of final Ligand-Protein complexes. The identified novel leads are further evaluated with ADME properties for their druglikeness activity. The overall insights can further expedite for the development of novel molecular entities as potential inhibitors against PHD3 in type 2 diabetes mellitus.


Keywords: PHD3, homology model, VMD-NAMD, Prime-MM/GBSA, ADME, type 2 diabetes mellitus.

Downloads

Download data is not yet available.

Author Biographies

Goverdhan Lanka, Molecular Modeling Laboratory, Department of Chemistry, Nizam College, Osmania University, Basheerbagh, Hyderabad-500001

Molecular Modeling Laboratory, Department of Chemistry, Nizam College, Osmania University, Basheerbagh, Hyderabad-500001

Revanth Bathula, Molecular Modeling Laboratory, Department of Chemistry, Nizam College, Osmania University, Basheerbagh, Hyderabad-500001

Molecular Modeling Laboratory, Department of Chemistry, Nizam College, Osmania University, Basheerbagh, Hyderabad-500001

Manan Bhargavi, Molecular Modeling Laboratory, Department of Chemistry, Nizam College, Osmania University, Basheerbagh, Hyderabad-500001

Molecular Modeling Laboratory, Department of Chemistry, Nizam College, Osmania University, Basheerbagh, Hyderabad-500001

Sarita Rajender Potlapally, Molecular Modeling Laboratory, Department of Chemistry, Nizam College, Osmania University, Basheerbagh, Hyderabad-500001

Molecular Modeling Laboratory, Department of Chemistry, Nizam College, Osmania University, Basheerbagh, Hyderabad-500001

References

1. Velloso LA, Eizirik DL, Cnop M. Type 2 diabetes mellitus—an autoimmune disease?. Nat Rev Endocrinol, 2013; 9(12):750-5.
2. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory desease. Nat Rev Immun, 2011; 11(2):98-107.
3. Chaudhuri A, Duvoor C, Reddy Dendi VS et al. Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management. Front Endocrinol, 2017; 8:6.
4. Ramakrishnan SK, Shaw YM. A central role for hypoxia-inducible factor (HIF)-2 in hepatic glucose homeostasis. J Nutr Health Aging, 2017;4(3):207-216.
5. Eltzschig HK, Bratton DL, Colgan SP. Targeting the hypoxia signaling for the treatment of ischaemic and inflammatory diseases. Nat Rev Drug Discov, 2014; 13(11):852-69.
6. Taniguchi CM, Finger EC, Krieg AJ, Wu C, Diep AN et al. Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes. Nat Med, 2013; 19(10):1325–1330.
7. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM. Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor. J Biol Chem, 2004; 279(37):38458-38465.
8. Cheng K, Ho K, Stokes R, et al. Hypoxia-inducible factor-1 alpha regulates beta cell function in mouse and human islets. J Clin Invest, 2010; 120(6):2171-83.
9. Xiang Z. Advances in Homology Protein Structure Modeling. Curr Protein Pept Sci, 2006; 7(3):217–227.
10. Kerfeld CA, Scott KM. Using BLAST to Teach “‘ E-value-tionary ’” Concepts. PLoS Biol, 2011; 9(2): e1101014.
11. Sievers F, Higgins DG. Clustal Omega, accurate alignment of very large numbers of sequences. Methods Mol Biol, 2014; 1079:105-16.
12. Philips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. J Comput Chem, 2005;26(16):1781-1802.
13. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst, 1993; 26:283-291.
14. Anderson AC. The Process of Structure-Based Drug Design. Chem Biol, 2003; 10(9):787–797.
15. Halgren TA. Identifying and characterizing binding sites and assessing druggability. J. Chem Inf Model, 2009;49(2):377–389.
16. Tian W, Chen C, Lei X, Zhao J, Liang J. CASTp 3.0: Computed atlas of surface topography of proteins. Nucleic Acids Res, 2018;46:W363-W367.
17. Bhargavi M, Sivan SK, Potlapally SR. Identification of novel anti-cancer agents by applying Insilico methods for inhibition of TSPO protein. Comput Biol Chem, 2017; 68:43-55.
18. QikProp, Schrödinger, LLC, New York, NY, 2011.
19. Prime v, Schrödinger, LLC, New York, NY, 2011.
20. Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res, 2003; 31(13):3784–3788.
21. Rajender PS, Vasavi M, Vuruputuri U. Identification of novel selective antagonists for cyclin C by homology modeling and virtual screening. Int J Biol Macromol, 2011; 48(2):292-300.
22. Kini RM, Evans HJ. Molecular modeling of proteins: A startegy for energy minimization by molecular mechanics in the AMBER force filed. J Biomol Struct, 1991;9(3):475-88.
23. Gunasekaran K, Ramakrishnan C, Balaram P. Disallowed Ramachandran conformations of amino acid residues in protein structures. J Mol Biol, 1996; 264(1):191-8.
24. Sippl MJ. Recognition of Errors in Three-Dimensional Structures of Proteins. Proteins: Struct Funct Genet, 1993; 17(4):355-362.
25. Halgren T. New Method for Fast and Accurate Binding-site identification and Analysis, Chem Biol Drug Des, 2007; 69(2):146–148.
26. LigPrep, Schrödinger, LLC, New York, NY, 2018.
27. Sastry GM, Adzhigirey M, Sherman W. Protein and ligand preparation : parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des, 2013; 27(3):221-34.
28. Pérez-Regidor L, Zarioh M, Ortega L, Martin-Santamaria S. Virtual Screening Approaches towards the Discovery of Toll-Like Receptor Modulators. Int J Mol Sci, 2016; 17(9):1508.
29. Butina D, Segall MD, Frankcombe K. Predicting ADME properties insilico: methods and models, Drug discovery today. Drug Discov Today, 2002; 7(11):S83-8.
Statistics
175 Views | 221 Downloads
How to Cite
1.
Lanka G, Bathula R, Bhargavi M, Potlapally SR. Homology modeling and molecular docking studies for the identification of novel potential therapeutics against human PHD3 as a drug target for type 2 diabetes mellitus. JDDT [Internet]. 15Jul.2019 [cited 3Mar.2021];9(4):265-73. Available from: http://www.jddtonline.info/index.php/jddt/article/view/3039
Issue
Vol 9 No 4 (2019): Volume 9, Issue 4, July-August 2019
Section
Research
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).